Puberty After Childhood Cancer: Why Normal Testosterone Doesn't Tell the Whole Fertility Story

By Dr. Payal Patel | LIFE Pediatric Endocrinology

Key Takeaways

• Normal testosterone levels do not necessarily mean normal sperm production or future fertility.
• Childhood chemotherapy and radiation can affect different parts of testicular function, sometimes without obvious symptoms.
• A 2026 study of 221 male childhood cancer survivors found that certain FSH patterns during puberty were associated with sperm production problems in adulthood.
• Elevated FSH during adolescence does not automatically mean permanent infertility.
• Individualized endocrine follow-up can help families understand hormonal development, treatment-related risks, and appropriate fertility referrals.

Can a Boy Have Normal Testosterone but Still Have Fertility Problems?

Yes. A boy who survived childhood cancer can have normal testosterone levels and progress through puberty while still having an increased risk of impaired sperm production later in life.

This is because the testes have two important but distinct functions: producing testosterone and producing sperm.

Testosterone helps drive many of the physical changes associated with male puberty, including a deeper voice, increased muscle mass, and sexual development. Sperm production, however, depends on different cells and hormonal signals.

Some childhood cancer treatments can affect sperm-producing cells more severely than testosterone-producing cells.

For parents, this distinction matters. A teenager may appear to be developing normally, have reassuring testosterone results, and still benefit from a more comprehensive evaluation of reproductive health.

New research published in JAMA Network Open in October 2026 provides important insight into why these differences deserve attention.

What New Research Reveals About Puberty and Fertility After Childhood Cancer

In a study published October 9, 2026, researchers examined reproductive hormone measurements and later outcomes in 221 male survivors of childhood cancer.

The researchers evaluated how hormone levels during puberty related to adult reproductive outcomes, including sperm production and the need for testosterone replacement therapy.

Their findings highlighted three important observations.

1. Elevated FSH During Puberty May Signal Future Sperm Production Problems

Follicle-stimulating hormone (FSH) helps regulate sperm production in males.

The study found that higher FSH measurements during adolescence were associated with azoospermia, a condition in which no sperm are detected in the semen, during adulthood.

This association was particularly relevant among survivors who had received testicular radiation.

The findings suggest that certain reproductive hormone measurements during puberty may help identify patients who would benefit from closer follow-up and fertility counseling.

However, FSH is not a definitive fertility test, and these findings do not establish a universally applicable diagnostic cutoff for adolescents.

2. Some Hormonal Abnormalities May Improve Over Time

One of the study's important findings involved boys exposed to intermediate doses of alkylating chemotherapy.

In some survivors, elevated FSH during adolescence returned toward normal levels by adulthood.

This suggests that reproductive hormone patterns can change as a young person matures.

An abnormal FSH result at age 14 or 16 should therefore not automatically be interpreted as evidence of permanent infertility.

The type of cancer treatment, cumulative exposure, pubertal development, and changes in hormone levels over time all contribute to the clinical picture.

3. Testosterone Production May Remain Normal Despite Fertility Risk

The researchers also found that testosterone-producing cells were comparatively resistant to certain treatment-related effects.

In some survivors, testosterone levels remained within expected ranges despite evidence suggesting impaired sperm production.

This distinction is particularly important for families who have been reassured by normal testosterone results.

Normal testosterone can be reassuring about one aspect of testicular function, but it cannot independently establish normal fertility.

Understanding Testosterone, FSH, and LH After Childhood Cancer

Three hormones are especially relevant when evaluating male pubertal development after childhood cancer treatment.

These hormones provide different pieces of information.

For example, a teenager may have a normal testosterone concentration but an elevated FSH level.

That pattern may raise concern about sperm-producing function, particularly in someone with a history of potentially gonadotoxic cancer treatment.

Similarly, an elevated LH level with normal testosterone may suggest that the body is working harder to maintain testosterone production.

Neither pattern should be interpreted without considering age, pubertal stage, treatment history, and the laboratory's appropriate reference ranges.

How Can Childhood Cancer Treatment Affect Puberty and Future Fertility?

Not every childhood cancer survivor faces the same reproductive risks.

The potential effects depend on several factors, including the type of treatment, cumulative doses, treatment location, and age at exposure.

Chemotherapy

Certain chemotherapy medications, particularly alkylating agents, can damage cells involved in sperm production.

Examples include cyclophosphamide and ifosfamide.

The risk varies considerably with cumulative exposure and other treatments received.

Importantly, normal testosterone production after chemotherapy does not rule out impaired sperm production.

Radiation Therapy

Radiation involving the testes can affect sperm-producing tissue and, at higher exposures, testosterone-producing cells.

Radiation involving the brain or pituitary region may also interfere with the hormonal signals responsible for initiating and maintaining puberty.

These are different mechanisms of injury and may require different endocrine evaluations.

Stem Cell Transplantation

Children who undergo hematopoietic stem cell transplantation may receive intensive chemotherapy, total-body irradiation, or both.

Depending on the treatment regimen, these survivors may face increased risks of reproductive and endocrine complications.

The most meaningful assessment begins with understanding exactly which treatments a child received.

Does Normal Puberty Mean a Childhood Cancer Survivor Will Be Fertile?

No. Normal pubertal development does not guarantee future fertility.

A boy may experience expected physical changes, including voice deepening, genital development, and facial hair growth, even when sperm production has been affected.

This is possible because the biological processes responsible for testosterone production and sperm production are related but not identical.

For families, the goal is not to assume that every survivor will experience fertility problems.

Instead, it is to recognize that outward pubertal development alone cannot answer every question about reproductive health.

A careful evaluation can help determine whether additional monitoring or counseling is appropriate.

What Hormone Tests Should Childhood Cancer Survivors Have During Puberty?

There is no single laboratory panel that every childhood cancer survivor needs.

Testing should be individualized according to treatment exposure, clinical symptoms, pubertal development, and existing survivorship recommendations.

Depending on the circumstances, a pediatric endocrinologist may consider:

• FSH: To assess hormonal signals associated with the sperm-producing system.
• LH: To evaluate the signaling pathway responsible for testosterone production.
• Morning total testosterone: To assess testosterone production using age- and puberty-appropriate interpretation.
• Additional endocrine testing: When there are concerns about delayed puberty, growth, thyroid function, or pituitary injury.

Hormone testing should be interpreted alongside a clinical assessment, not in isolation.

A normal FSH level cannot definitively confirm normal sperm production. Likewise, elevated FSH does not independently establish permanent infertility.

When developmentally appropriate, semen analysis may provide more direct information about sperm production. This should be discussed sensitively with the patient and appropriate specialists.

For children exposed to treatments that may affect the hypothalamus or pituitary gland, broader endocrine surveillance may also be indicated.

When Should a Childhood Cancer Survivor See a Pediatric Endocrinologist?

An endocrine evaluation may be particularly helpful when a survivor has:

• Delayed or unexpectedly slow pubertal progression.
• Concerns about growth or height development.
• Abnormal FSH, LH, or testosterone measurements.
• A history of testicular radiation or potentially gonadotoxic chemotherapy.
• Prior radiation involving the hypothalamic-pituitary region.
• Questions about future reproductive health or fertility preservation.

Importantly, some survivors benefit from scheduled endocrine surveillance even without symptoms.

Pediatric endocrinology care should complement, rather than replace, the patient's oncology survivorship program.

For fertility-specific concerns, collaboration with reproductive urology or fertility preservation specialists may also be appropriate.

Can Fertility Recover After Childhood Cancer Treatment?

In some cases, aspects of reproductive function may recover or improve over time.

The 2026 JAMA Network Open study found that certain survivors exposed to intermediate doses of alkylating chemotherapy experienced normalization of elevated FSH measurements by adulthood.

However, normalization of FSH does not by itself prove that fertility has recovered.

Similarly, persistently elevated FSH may indicate increased risk without establishing that biological parenthood will be impossible.

Recovery depends on individual circumstances, and fertility outcomes cannot be reliably predicted from one adolescent laboratory result.

This is why longitudinal follow-up and thoughtful counseling are so important.

The LIFE Approach: Looking Beyond a Single Hormone Result

At LIFE Pediatric Endocrinology, we believe meaningful endocrine care begins with understanding the whole patient.

For a child or adolescent who has completed cancer treatment, that means considering more than whether an individual laboratory value falls within a reference range.

A comprehensive endocrine assessment may include reviewing:

Growth and development: Is the child growing appropriately, and is puberty progressing as expected?

Cancer treatment history: Were there exposures that could affect the testes, hypothalamus, pituitary gland, or other endocrine organs?

Hormonal function: What do testosterone, FSH, LH, and other clinically indicated measurements reveal when interpreted together?

Long-term health: Are there additional endocrine concerns that warrant surveillance or coordination with the survivorship team?

Patient and family goals: What questions or concerns matter most to the adolescent and family as they plan for the future?

Our approach emphasizes individualized assessment, evidence-based medicine, and coordinated care.

Nutrition, sleep, physical activity, and overall metabolic health also play important roles in supporting healthy adolescent development. However, lifestyle measures cannot be assumed to reverse chemotherapy- or radiation-related damage to sperm-producing cells.

For families navigating life after childhood cancer, thoughtful care means understanding what is known, acknowledging uncertainty, and developing an appropriate plan for the years ahead.

Frequently Asked Questions

Can chemotherapy cause infertility even if testosterone is normal?

Yes. Certain chemotherapy treatments can impair sperm-producing cells while testosterone production remains relatively preserved. Normal testosterone does not rule out fertility problems.

What does high FSH mean in a teenage boy after chemotherapy?

Elevated FSH may suggest that the testes are not responding normally to signals involved in sperm production. However, interpretation depends on pubertal stage, treatment exposure, laboratory reference ranges, and hormone trends. High FSH alone does not prove permanent infertility.

Can childhood cancer survivors have children naturally?

Yes. Many childhood cancer survivors can have biological children, although fertility potential varies according to treatment history and individual circumstances. Some may require reproductive assistance, while others have no significant fertility impairment.

Can a boy go through normal puberty and still be infertile?

Yes. The hormonal processes responsible for physical pubertal development can remain functional even when sperm production has been damaged.

At what age should fertility be evaluated after childhood cancer?

The timing depends on treatment-related risk, pubertal development, patient maturity, and survivorship recommendations. Fertility preservation counseling should ideally occur before gonadotoxic treatment whenever feasible. Follow-up discussions may be appropriate during adolescence and young adulthood.

Is FSH or testosterone more important for predicting fertility?

Neither hormone independently establishes fertility. FSH may provide information about sperm-producing function, while testosterone primarily reflects androgen production. When appropriate, semen analysis offers more direct information about sperm production.

Does high FSH at age 14 mean a boy will be infertile as an adult?

No. Research has identified associations between elevated adolescent FSH and later sperm production problems in some childhood cancer survivors. However, individual outcomes vary, and some hormonal abnormalities improve with age.

Looking Ahead: Supporting Healthy Development After Childhood Cancer

Surviving childhood cancer is an extraordinary milestone. As children move into adolescence and adulthood, attention naturally expands toward growth, puberty, hormonal health, and future reproductive choices.

The latest research reminds us that these aspects of health cannot always be understood through a single test.

A normal testosterone level can be reassuring, but it does not tell the complete fertility story.

Likewise, an abnormal FSH result deserves careful interpretation rather than premature conclusions.

For families, the most valuable next step is an individualized assessment that considers the child's treatment history, current development, and long-term goals.

At LIFE Pediatric Endocrinology, we help families navigate complex questions about growth, puberty, and hormonal development through personalized, evidence-informed care.

If your child has a history of cancer treatment and you have questions about puberty or endocrine health, our team can help determine whether a comprehensive pediatric endocrine evaluation is appropriate.

Schedule a Consultation With LIFE Pediatric Endocrinology

About The Author

Dr. Payal Patel, MD, is a board-certified pediatric endocrinologist at LIFE Pediatric Endocrinology with more than a decade of experience caring for children and adolescents with complex hormonal conditions.

Before joining LIFE, Dr. Patel practiced at Phoenix Children’s and Banner Health in Arizona, where she became particularly known for her work with pediatric cancer survivors experiencing growth and pubertal complications following chemotherapy and other cancer treatments.

Her expertise extends beyond traditional pediatric endocrinology, with a special focus on helping children navigate the long-term hormonal effects of cancer treatment, including growth disorders, delayed puberty, and reproductive development.

Today, Dr. Patel brings this specialized experience to LIFE Pediatric Endocrinology in Scottsdale, Arizona, combining advanced endocrine evaluation with a personalized, integrative approach to care. Her goal is to help every child achieve their fullest potential while giving families clarity, confidence, and a thoughtful plan for long-term health.

Medical Research Reference

Koskela M, Duffin K, Korhonen M, et al. Pubertal Testicular Function in Childhood Cancer Survivors and Future Fertility. JAMA Network Open. Published October 9, 2026;9(10).

DOI: https://doi.org/10.1001/jamanetworkopen.2026.38294

Medical disclaimer: This article is intended for educational purposes and does not replace individualized medical advice. Hormonal evaluation, fertility assessment, and survivorship care should be tailored to each patient's clinical circumstances.